131
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Evaluation of Hematological Parameters in the Genetic Prospective in Epileptic Patients of Khyber Pakhtunkhwa

, & ORCID Icon
Pages 377-385 | Published online: 23 Dec 2019

References

  • World Health Organization. Global Burden of Epilepsy and the Need for Coordinated Action at the Country Level to Address Its Health, Social and Public Knowledge Implications; 2015.
  • Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005;66(1):63–74. doi:10.1016/j.eplepsyres.2005.07.00216125900
  • Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650–655. doi:10.1016/j.seizure.2010.10.02721075011
  • Lewis SM, Bain BJ, Bates I, Dacie JV. Dacie and Lewis Practical Haematology. Elsevier Health Sciences; 2006.
  • Behrens JA, Brown WP, Gibson DF, Detter JC. Whole-blood hemoglobin determinations: a comparison of methodologies. Am J Clin Pathol. 1979;72(6):904–908. doi:10.1093/ajcp/72.6.904517459
  • Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 2005;80(7):923-936.
  • Aronson JK. Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions. Elsevier; 2005.
  • Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802. doi:10.1016/S1474-4422(12)70153-922832500
  • Bertolino J. Carbamazepine. What physicians should know about its hematologic effects. Postgrad Med. 1990;88(1):183–186. doi:10.1080/00325481.1990.117163702367254
  • Tohen M, Castillo M, Zarate C Jr. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2228 patients at risk. Women. 1995;13(72.2):6–85.7.
  • Olcay L, Pekcan S, Yalnizoğlu D, Büyükpamukçu M, Yalaz K. Fatal agranulocytosis developed in the course of carbamazepine therapy. A case report and review of the literature. Turk J Pediatr. 1994;37(1):73–77.
  • Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry. 1984;141(5):687–688.6711691
  • Holmes G. Carbamazepine: Adverse Effects. Antiepileptic Drugs. Philadelphia: Lippincott-Raven; 2002:284–297.
  • Isojärvi JI, Pakarinen AJ, Myllylä VV. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B 12 levels during carbamazepine and oxcarbazepine therapy. Seizure. 1997;6(3):207–211. doi:10.1016/S1059-1311(97)80007-69203249
  • Salomon O, Rosenberg N, Zivelin A, et al. Methionine synthase A2756G and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors for idiopathic venous thromboembolism. Hematol J. 2001;2(1):38–41. doi:10.1038/sj.thj.620007811920232
  • Lalouschek W, Aull S, Serles W, et al. The relation between erythrocyte volume and folate levels is influenced by a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene (C677T). J Invest Med. 2000;48(1):14–20.
  • Banka S, Blom HJ, Walter J, et al. Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Human Genetics. 2011;88(2):216–225. doi:10.1016/j.ajhg.2011.01.00421310276
  • Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual Available from: https://apps.who.int/iris/handle/10665/40062. Accessed date 4 August 2014.
  • Bhosale UA, Loharkar NR, Yegnanarayan R, Quraishi N. Study of effects of antiepileptic therapy on various biochemical and hematological parameters patients suffering of epilepsy. Int J Basic Clin Pharmacol. 2014;3(1):79–85. doi:10.5455/2319-2003.
  • Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Nat Acad Sci. 1998;95(22):13217–13220. doi:10.1073/pnas.95.22.132179789068
  • Christensen B, Arbour L, Tran P, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet. 1999;84(2):151–157. doi:10.1002/(ISSN)1096-862810323741
  • Brosh K, Matok I, Sheiner E, et al. Teratogenic determinants of first-trimester exposure to antiepileptic medications. J Popul Ther Clin Pharmacol. 2010;18:e89–98.
  • Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Nat Acad Sci. 2009;106(36):15424–15429. doi:10.1073/pnas.090207210619706381
  • Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19(1):217–246. doi:10.1146/annurev.nutr.19.1.21710448523
  • Bachmann T, Bertheussen K, Svalheim S, et al. Haematological side effects of antiepileptic drug treatment in patients with epilepsy. Acta Neurol Scand. 2011;124(s191):23–27. doi:10.1111/ane.2011.124.issue-s191
  • Handoko KB, Souverein PC, Van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006;47(7):1232–1236. doi:10.1111/j.1528-1167.2006.00596.x16886988
  • Farkas V, Szabo M, Renyi I, Kohlheb O, Benninger C. Temporary pure red-cell aplasia during valproate monotherapy: clinical observations and spectral electroencephalographic aspects. J Child Neurol. 2000;15(7):485–487. doi:10.1177/08830738000150071310921523
  • Jang SH, Choi EK, Eun SH, Kim SJ. Changes of body weight and lipid profiles according to apolipoprotein E polymorphism in children with antiepileptics. Korean J Pediatr. 2002;45(1):88–94.
  • Sankar R. Initial treatment of epilepsy with antiepileptic drugs pediatric issues. Neurology. 2004;63(10 suppl 4):S30–S9. doi:10.1212/WNL.63.10_suppl_4.S3015557549
  • Pee DH, Park YK, Eun BL, Park SH, Kim SK. The hematologic effect of antiepileptic drug. Korean J Pediatr. 1997;40(2):217–224.
  • Aliyu H, Ambali JOASF, Abdulkadir UZ. Effects of administration of carbamazepine and/or phenytoin on haematological parameters in wistar rats. Afr J Pharm Pharmacol. 2013;7(23):1585–1591. doi:10.5897/AJPP2013.3611